Thibaut Fayet

Outlook Microsoft Office 365 WordPress.org Mobile Friendly Apache reCAPTCHA Google Tag Manager Nginx Google Analytics Remote AI

biotechnology phage innovation bacterial infection viruses staphylococcus aureus escherichia coli pseudomonas aeruginosa phxm phage therapy antimicrobial resistance bacteriophage clinical trials fda approval drug resistance antimicrobial treatments targeted therapy microbial infections antibiotic alternatives clinical portfolio hospital-acquired infections biopharmaceutical company clinical-stage therapeutic innovation precision medicine infection control medical research bacterial infections therapeutic strategy investigator-initiated studies bacteriophage therapy public health surgical infections medical biotechnology clinical development biotech merger healthcare solutions microbial resistance infectious disease high specificity patent portfolio research & development gmp standards healthcare challenges individualized treatment vaccine alternatives international health threats biomedical innovation drug development scientific partnerships healthcare investments clinical efficacy biotechnology sector future healthcare resistant bacterial infections clinical-stage biopharmaceutical innovative treatments critical care individualized phage therapies (ipt) phage therapies medicinal products (ptmp) compassionate use authorization prosthetic joint infections healthcare innovation biopharmaceutical industry specialty pharma therapeutic pipeline strategic collaborations patient access phage-based treatments financial restructuring market positioning european hospitals advanced infection management health care health wellness & fitness hospital & health care